Androgen Replacement

FDA Background Documents For The Discussion Of Two Major Issues In Testosterone Replacement Therapy (TRT): http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM412536.pdf

1. The appropriate indicated population for TRT, and
2. The potential for adverse cardiovascular outcomes associated with use of TRT
 
Narayanan K, Havmoeller R, Reinier K, et al. Sex Hormone Levels in Patients with Sudden Cardiac Arrest. Heart Rhythm. http://www.heartrhythmjournal.com/article/S1547-5271(14)00920-5/abstract

Background - Sex hormones are known to have significant effects on pathophysiology of cardiovascular disease.

Objective - To study the association between sex hormone levels and sudden cardiac arrest (SCA).

Methods - In the ongoing Oregon Sudden Unexpected Death Study (catchment population approximately 1 million), cases of SCA were compared with matched controls. Testosterone and estradiol levels were measured from blood samples drawn at the time of the SCA event in cases and during a routine visit in controls.

Results - Among cases (n=149; 64.1 ± 11.7 years; 73.2% male), compared to controls (n=149; 64.2 ±11.6 years; 72.5% male), median testosterone levels were significantly lower in males (4.4 vs. 5.4 ng/ml; p=0.01). Median estradiol levels were higher in male (68 vs. 52 pg/ml; p<0.001) and female cases (54 vs. 36 pg/ml; p<0.001). In multivariate analysis, higher testosterone levels were associated with lower SCA odds only in males (OR 0.75; 95% CI 0.58-0.96; p=0.02). Higher estradiol levels were associated with higher SCA odds in both males (OR 2.0; 95% CI 1.5-2.6; p<0.001) and females (OR 3.5; 95% CI 1.9-6.4; p<0.001). A higher testosterone/estrogen ratio was associated with lower SCA odds in males only (OR 0.5; 95% CI 0.4-0.7; p<0.001). In a canine model of SCA, plasma testosterone levels were not significantly altered by the cardiac arrest event.

Conclusions - We observed significant differences in sex hormone levels in patients who suffered SCA, with potential mechanistic implications. The role of sex hormones in the genesis of fatal ventricular arrhythmias warrants further exploration.
 
FDA: LITTLE EVIDENCE TO SUPPORT TESTOSTERONE DRUGS
http://hosted.ap.org/dynamic/stories/U/US_TESTOSTERONE_THERAPY_FDA

WASHINGTON (AP) -- The Food and Drug Administration says there is little evidence that testosterone-boosting drugs taken by millions of American men are beneficial, though the agency is also unconvinced by studies suggesting the hormone carries serious risks.

The agency posted its review online Wednesday ahead of a public meeting to discuss the benefits and risks of treatments that raise levels of the male hormone. Regulators agreed to convene the September 17 meeting after two federally funded studies found links between testosterone therapy and heart problems in men.

The scrutiny comes amid an industry marketing blitz for new pills, patches and formulations that has transformed testosterone a multibillion-dollar market. Advertisements for prescription gels like Fortesta and Androgel promise aging men relief from "Low-T," a condition they link to low libido, fatigue and weight gain.

But FDA reviewers state that "the need to replace testosterone in these older men remains debatable." While testosterone levels naturally decline after age 40, it's unclear whether those lower levels actually lead to the signs commonly associated with aging, including decreased energy and loss of muscle.

...
The agency will ask its panel of outside experts this month whether the prescribing information on testosterone drugs should be revised to focus on a narrower group of patients.

The panelists will also be asked to weigh in on two recent studies that showed higher rates of cardiovascular problems in men using testosterone.
 
Muraleedharan V, Hugh Jones T. Testosterone and mortality. Clinical Endocrinology 2014;81(4):477-87. http://onlinelibrary.wiley.com/doi/10.1111/cen.12503/full

Epidemiological studies have found that men with low or low normal endogenous testosterone are at an increased risk of mortality than those with higher levels.

Cardiovascular disease accounts for the greater proportion of deaths in those with low testosterone. Cancer and respiratory deaths in some of the studies are also significantly more prevalent. Disease-specific studies have identified that there are higher mortality rates in men with cardiovascular, respiratory and renal diseases, type 2 diabetes and cancer with low testosterone. Obesity, metabolic syndrome, type 2 diabetes, cardiovascular disease and inflammatory disorders are all associated with an increased prevalence of testosterone deficiency.

Two major questions that arise from these findings are
(1) is testosterone deficiency directly involved in the pathogenesis of these conditions and/or a contributory factor impairing the body's natural defences or is it merely a biomarker of ill health and the severity of underlying disease process?
(2) Does testosterone replacement therapy retard disease progression and ultimately enhance the clinical prognosis and survival?

This review will discuss the current state of knowledge and discuss whether or not there are any answers to either of these questions.

There is convincing evidence that low testosterone is a biomarker for disease severity and mortality. Testosterone deficiency is associated with adverse effects on certain cardiovascular risk factors that when combined could potentially promote atherosclerosis.

The issue of whether or not testosterone replacement therapy improves outcomes is controversial. Two retrospective studies in men with diagnosed hypogonadism with or without type 2 diabetes have reported significantly improved survival.
 
Scovell JM, Ramasamy R, Lipshultz LI. Re: Testosterone Lab Testing and Initiation in the United Kingdom and the United States, 2000 to 2011. Eur Urol 2014;66(4):786-7. http://www.europeanurology.com/article/S0302-2838(14)00740-4/fulltext/re-testosterone-lab-testing-and-initiation-in-the-united-kingdom-and-the-united-states-2000-to-2011

Experts’ summary: The retrospective cohort study by Layton and colleagues sought to describe the patterns of testosterone testing and testosterone prescriptions in men in the United Kingdom and the United States. The authors utilized data from general practitioner health care records in the United Kingdom and from both commercial and Medicare insurance claims in the United States between 2000 and 2011. This study found that testosterone testing rates increased in both countries and that new testing in untreated patients rose threefold in the United Kingdom and more than fourfold in the United States. This study observed that a significant proportion of men in their reproductive years received testosterone supplementation. Men aged 18–39 yr accounted for a significant minority of new testosterone prescriptions (United Kingdom: 16%; United States: 12%), and a higher proportion of US men with normal or high serum testosterone levels received testosterone prescriptions (United Kingdom: 1%; United States: 4–9%). This discrepancy in testing and diagnosis was also evident from the fact that in the United Kingdom, 88% of men who were prescribed testosterone were diagnosed with clinical or laboratory hypogonadism compared with only 60% of men in the United States.

Experts’ comments: The study by Layton et al., using data from both UK and US cohorts, highlights the discrepancies between a definitive diagnosis of hypogonadism and interventional treatment. This study, along with an analysis performed by Baillargeon and colleagues http://www.europeanurology.com/article/S0302-2838(14)00740-4/fulltext/re-testosterone-lab-testing-and-initiation-in-the-united-kingdom-and-the-united-states-2000-to-2011#bib0005 ([1]), provides evidence for what we already see in clinical practice, namely, that the number of testosterone therapy prescriptions has risen dramatically over the past decade. Because practitioners have become more aware of hypogonadism, we would hope to see an increase in laboratory testing but with a smaller increase in testosterone therapy. These data, however, demonstrate an alarming trend. A subset of patients are not receiving adequate testing http://www.europeanurology.com/article/S0302-2838(14)00740-4/fulltext/re-testosterone-lab-testing-and-initiation-in-the-united-kingdom-and-the-united-states-2000-to-2011#bib0010 ([2])prior to initiation of testosterone therapy, and more men are being prescribed testosterone therapy despite no clinical or laboratory diagnosis of hypogonadism. This study provides clear evidence that guidelines for testosterone therapy initiation are seldom followed, and in the United States, the lack of adherence to guidelines has led to an overabundance of potentially unnecessary testosterone prescriptions.

Another alarming trend highlighted in the study is that in both countries, >10% of men initiating testosterone therapy are within their reproductive years. Practitioners often, do not consider the inhibitory effect of exogenous testosterone on a male's reproductive potential. In fact, a 2010 survey of American Urological Association members found that up to 25% of urologists would prescribe testosterone therapy for idiopathic male infertility http://www.europeanurology.com/article/S0302-2838(14)00740-4/fulltext/re-testosterone-lab-testing-and-initiation-in-the-united-kingdom-and-the-united-states-2000-to-2011#bib0015 ([3]), suggesting that the impact on fertility often is not only ignored but also incorrectly understood. A survey of Canadian men presenting at a male infertility clinic between 2008 and 2012 found that an alarming 39% of the men on testosterone therapy received the prescription from either an endocrinologist or a urologist http://www.europeanurology.com/article/S0302-2838(14)00740-4/fulltext/re-testosterone-lab-testing-and-initiation-in-the-united-kingdom-and-the-united-states-2000-to-2011#bib0020 ([4]). This finding suggests that a large group of men desiring fertility are receiving testosterone supplementation from practitioners outside the fields of endocrinology or urology and that some endocrinologists or urologists are not appropriately considering the ramifications of exogenous testosterone on fertility. The reported discrepancy between adequate testing and new testosterone prescriptions highlights the need for increased physician education and the proper management of these patients by practitioners trained in appropriately diagnosing and treating male hypogonadism.

References

http://www.europeanurology.com/article/S0302-2838(14)00740-4/fulltext/re-testosterone-lab-testing-and-initiation-in-the-united-kingdom-and-the-united-states-2000-to-2011#back-bib0005 ([1]) J. Baillargeon, R.J. Urban, K.J. Ottenbacher, K.S. Pierson, J.S. Goodwin. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173:1465-1466. http://archinte.jamanetwork.com/article.aspx?articleid=1691925

http://www.europeanurology.com/article/S0302-2838(14)00740-4/fulltext/re-testosterone-lab-testing-and-initiation-in-the-united-kingdom-and-the-united-states-2000-to-2011#back-bib0010 ([2]) S. Bhasin, G.R. Cunningham, F.J. Hayes, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-2559. http://press.endocrine.org/doi/full/10.1210/jc.2009-2354

http://www.europeanurology.com/article/S0302-2838(14)00740-4/fulltext/re-testosterone-lab-testing-and-initiation-in-the-united-kingdom-and-the-united-states-2000-to-2011#back-bib0015 ([3]) E.Y. Ko, K. Siddiqi, R.E. Brannigan, E.S. Sabanegh Jr. Empirical medical therapy for idiopathic male infertility: a survey of the American Urological Association. J Urol. 2012;187:973-978. http://www.jurology.com/article/S0022-5347(11)05460-7/abstract

http://www.europeanurology.com/article/S0302-2838(14)00740-4/fulltext/re-testosterone-lab-testing-and-initiation-in-the-united-kingdom-and-the-united-states-2000-to-2011#back-bib0020 ([4]) M.K. Samplaski, Y. Loai, K. Wong, K.C. Lo, E.D. Grober, K.A. Jarvi. Testosterone use in the male infertility population: prescribing patterns and effects on semen and hormonal parameters. Fertil Steril. 2014;101:64-69. http://www.fertstert.org/article/S0015-0282(13)03053-7/abstract
 
Bosland MC. Testosterone Treatment is a Potent Tumor Promoter for the Rat Prostate. Endocrinology:en.2014-1688. http://press.endocrine.org/doi/abs/10.1210/en.2014-1688

Testosterone is increasingly prescribed to middle aged and older men, but the safety of this treatment has been called into question and the possible risk of prostate cancer is unknown.

We treated Wistar WU rats chronically via slow-release Silastic implants with doses of testosterone that increased circulating levels in a dose-related fashion with or without a preceding single injection of the carcinogen N-nitroso-N-methylurea (MNU).

Without MNU, testosterone induced prostate carcinomas in 10–18% of rats and after MNU injection, testosterone treatment caused prostate cancer in 50–71% of rats with a very steep dose response, producing a 50% prostatic tumor incidence even at a testosterone dose that did not elevate circulating testosterone levels.

Prostate cancers did not occur in rats given MNU or no treatment, while testosterone alone induced a low incidence of prostate cancer and increased the number rats bearing tumors at other sites, particularly malignant tumors.

Thus, testosterone was shown to be a weak complete carcinogen and a strong tumor promoter for the rat prostate in this study. These findings have potential significant public health implications for the use of testosterone therapy in men.
 
Comparison of [WORTHLESS] Questionnaires Used For Screening and Symptom Identification in Hypogonadal Men

Bernie AM, Scovell JM, Ramasamy R. Comparison of questionnaires used for screening and symptom identification in hypogonadal men. Aging Male 2014:1-4. http://informahealthcare.com/doi/abs/10.3109/13685538.2014.963041

Late-onset hypogonadism (LOH) is typically defined as the cluster of symptoms appearing in aging men and accompanied by a decrease in serum testosterone levels.

The identification of a simple screening tool with a high level of sensitivity and specificity to predict LOH has remained a challenge.

To identify men with LOH, a variety of self-administered questionnaires have been developed including The Saint Louis University Androgen Deficiency in the Aging Male (ADAM) Questionnaire, The Quantitative ADAM (qADAM) Questionnaire, The Aging Male Symptoms (AMS) rating scale, The Massachusetts Male Aging Study (MMAS) questionnaire and The New England Research Institutes (NERI) hypogonadism questionnaire.

The applicability of these questionnaires in the clinical setting is debated because some of the symptoms associated with LOH could be attributed to the natural process of aging and comorbidities. The goal of this review is to compare the utility and the validity of the different LOH questionnaires.
 
Hirsch D, Benbassat C, Toledano Y, et al. Pituitary imaging findings in male patients with hypogonadotrophic hypogonadism. Pituitary. http://link.springer.com/article/10.1007/s11102-014-0601-x

CONTEXT: Data on pituitary imaging in adult male patients presenting with hypogonadotrophic hypogonadism (HH) and no known pituitary disease are scarce.

OBJECTIVE: To assess the usefulness of pituitary imaging in the evaluation of men presenting with HH after excluding known pituitary disorders and hyperprolactinemia. DESIGN: A historical prospective cohort of males with HH.

PATIENTS: Men who presented for endocrine evaluation from 2011 to 2014 with testosterone levels <10.4 nmol/L (300 ng/mL), normal LH and FSH levels and no known pituitary disease.

RESULTS: Seventy-five men were included in the analysis. Their mean age and BMI were 53.4 +/- 14.8 years and 30.7 +/- 5.2 kg/m2, respectively. Mean total testosterone, LH, and FSH were 6.2 +/- 1.7 nmol/L, 3.4 +/- 2 and 4.7 +/- 3.1 mIU/L, respectively. Prolactin level within the normal range was obtained in all men (mean 161 +/- 61, range 41-347 mIU/L).

Sixty-two men had pituitary MRI and 13 performed CT. In 61 (81.3 %) men, pituitary imaging was normal.

Microadenoma was found in 8 (10.7 %), empty sella and thickened pituitary stalk in one patient (1.3 %) each. In other four patients (5.3 %) a small or mildly asymmetric pituitary gland was noted.

No correlation was found between testosterone level and the presence of pituitary anomalies.

CONCLUSIONS: This study suggests that the use of routine hypothalamic-pituitary imaging in the evaluation of IHH, in the absence of clinical characteristics of other hormonal loss or sellar compression symptoms, will not increase the diagnostic yield of sellar structural abnormalities over that reported in the general population.
 
Ramasamy R, Wilken N, Scovell JM, Kovac JR, Lipshultz LI. Hypogonadal Symptoms Are Associated With Different Serum Testosterone Thresholds in Middle-aged and Elderly Men. Urology. https://www.sciencedirect.com/science/article/pii/S0090429514008309

OBJECTIVE: To determine the association between hypogonadal symptoms and total serum testosterone levels in middle-aged and elderly men (aged >40 years), and to identify whether there exists a clear-cut discriminatory threshold of total testosterone below which the probability of hypogonadal symptoms increases.

METHODS: We retrospectively reviewed the charts of 360 men who presented to an outpatient men's health clinic with a chief complaint of low testosterone. Sexual, psychological, and physical symptoms were evaluated using the androgen deficiency in the aging male (ADAM) questionnaire. Serum levels of total testosterone were collected on the same day on which men completed their ADAM questionnaires.

We performed the univariate (t test, chi-square, and binary logistic regression) and multivariate analyses (binary logistic regression) to evaluate the total testosterone threshold and the symptoms that predicted a low-testosterone level.

RESULTS: A cluster of symptoms: 1 sexual (decreased libido), 1 psychological (decreased energy), and 3 physical (decreased strength or endurance, decreased ability to play sports, and falling asleep after dinner) were most associated with total serum testosterone levels of </=300 ng/dL.

The threshold testosterone serum levels that were associated with an increased prevalence of these hypogonadal symptoms ranged from 320 to 375 ng/dL. On multivariate analysis, age, but not symptoms on the ADAM questionnaire, predicted a total testosterone level of <300 ng/dL.

CONCLUSION: A distinct constellation of hypogonadal symptoms exists at various serum testosterone levels. Consequently, identification of the thresholds for specific symptom management will be critical in establishing patient-centered treatment algorithms.
 
Doubts About Treating Hypogonadism Due to Long-term Opioid Use With Testosterone Therapy - A Teachable Moment
http://archinte.jamanetwork.com/article.aspx?articleID=1915872

[WTF! NOT FROM THIS BOZO!]

A man in his 40s with chronic low back pain treated with long-term opioid medication, depression, and hypogonadotrophic hypogonadism was referred to the endocrine clinic by his primary care physician to consider resumption of testosterone therapy.

One year prior to presentation, laboratory workup for depression revealed a serum testosterone level of 88 ng/dL, serum luteinizing hormone level less than 0.1 mIU/mL, serum follicle-stimulating hormone level less than 1.0 mIU/mL.

Testosterone therapy by injection was initiated and continued for 6 months with reported improvement of depressive symptoms, although he did experience occasional mood swings.

After 6 months of testosterone therapy, the patient experienced urinary retention and therapy was discontinued. After urologic consultation, it was determined that his lower urinary tract symptoms were most likely due to opioid medication use rather than prostatic enlargement.

Discussion with his primary care physician included attempts to taper his opioid medication use, but he was still referred for management of his hypogonadism.

In the endocrine clinic, he described a long history of fatigue, decreased libido, erectile dysfunction, and insomnia.

After a detailed discussion of potential benefits and risks, he expressed a strong desire to resume testosterone therapy given his former perceived improvement in mood.

Repeated laboratory evaluation reaffirmed hypogonadotrophic hypogonadism without other pituitary dysfunction. He was prescribed testosterone gel rather than injections in an attempt to mitigate his mood swings.

Testosterone therapy for hypogonadism is often directed at symptoms related to quality of life including restoration of libido, sexual dysfunction, energy level, and mood.

Yet, when these symptoms are studied in patients undergoing testosterone therapy, there is little evidence that use of exogenous testosterone has substantial or meaningful impact on these symptoms.

When compared with the potential harms of therapy including polycythemia, gynecomastia, acne, sleep apnea, infertility, and decreased bone mineral density, the lack of benefit is troubling.

Furthermore, several recent studies have indicated an increased risk of cardiovascular events with testosterone therapy.

Although large placebo-controlled randomized clinical trials are lacking, a 2010 randomized clinical trial examining testosterone use in frail older men was stopped early because of increased cardiovascular adverse events in the treatment group.

More recently, a large retrospective cohort trial of Veterans Affairs patients aged 60 to 63 years demonstrated that men with testosterone levels less than 300 ng/dL undergoing coronary angiography and subsequently starting testosterone therapy were at significantly greater risk of cardiovascular end points over 3 years compared with men who did not take testosterone: 25.7% vs 19.9% (hazard ratio, 1.29 [95% CI, 1.04-1.58]).

This information suggests potential and serious harm from testosterone therapy that may outweigh any benefit to quality of life.

Long-term opioid therapy has likely resulted in hypogonadism in this patient, which he believes has negatively affected his ability to enjoy life.

The treatment options available are to provide testosterone therapy or to address the underlying cause of his hypogonadism and taper or eliminate his opioid dose.

This latter approach would address his underlying endocrine dysfunction, spare him the known risks of high-dose opioids, and prevent any potential harm from exposure to exogenous testosterone.

In recognition of the fact that some patients require opioids to manage pain, it may not be feasible to substantially reduce his analgesic dosing.

However, without clear and clinically important benefit from testosterone therapy, especially in consideration of the potential serious harm of such therapy, it is difficult to justify its use in this patient.
 
European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) Review Does Not Confirm Increase in Heart Problems with Testosterone Medicines
http://goo.gl/7VK9BW

The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed an EU-wide review of testosterone-containing medicines following concerns over serious side effects on the heart and blood vessels, including heart attack.

The PRAC review did not find consistent evidence that the use of testosterone in men who do not produce enough testosterone (a condition known as hypogonadism) increases the risk of heart problems.

The committee considered that the benefits of testosterone continue to outweigh its risks but recommended that testosterone-containing medicines should only be used where lack of testosterone has been confirmed by signs and symptoms as well as laboratory tests.

The evidence about the risks of serious side effects on the heart of these medicines is inconsistent. While some studies including three recently published studies did suggest an increased risk of heart problems in men using testosterone compared with men not taking it, these studies had some limitations and others did not confirm this risk.

The PRAC also noted that the lack of testosterone itself could increase the risk of heart problems.

The PRAC therefore recommended that testosterone-containing medicines should only be used if the lack of testosterone has been confirmed by signs and symptoms as well as laboratory tests. The EU product information for all testosterone-containing medicines should be updated to include this recommendation as well as warnings against use in men suffering from severe heart, liver or kidney problems.

The limited data on safety and effectiveness in patients over 65 years of age as well as the fact that testosterone levels decrease with age and that age-specific testosterone reference values do not exist will be highlighted in the product information.

The safety of testosterone medicines should continue to be monitored. In particular, a number of studies are still ongoing and their results will be considered in future regular benefit-risk assessments for these medicines.
 
Grech A, Breck J, Heidelbaugh J. Adverse effects of testosterone replacement therapy: an update on the evidence and controversy. Ther Adv Drug Saf 2014;5(5):190-200. http://taw.sagepub.com/content/5/5/190.abstract

Testosterone replacement therapy (TRT) has been used in millions of men worldwide to treat diminished libido and erectile dysfunction, and to improve strength and physical function.

The estimated likelihood of adverse effects of long-term TRT is still essentially unknown, as overall high-quality evidence based upon prospective randomized trials to recommend for or against its use in most men with testosterone deficiency (TD) is lacking.

Evidence to suggest that TRT increases cardiovascular morbidity and mortality risks is poor, as results vary across study populations and their baseline comorbidities.

While TRT may increase serum prostate-specific antigen levels in some men, it often remains within clinically acceptable ranges, and has not been shown to increase the risk of prostate cancer.

Current literature supports that TRT does not substantially worsen lower urinary tract symptoms, and may actually improve symptoms in some men. Limited evidence suggests that TRT may initially worsen obstructive sleep apnea in some men, but that this is not a longstanding effect.

TRT may result in erythrocytosis in some men, however long-term studies have not reported significant adverse events (e.g. cerebrovascular accident, vascular occlusive events, venous thromboembolisms).

Future research will require dedicated focus on evaluation of large, multiethnic cohorts of men through prospective trials to better elucidate both risk and hazard ratios of TRT as it relates to cardiovascular disease, prostate cancer, lower urinary tract symptoms, obstructive sleep apnea, erythrocytosis, and other to-be-determined theoretical risks in men both with and without cardiovascular risk equivalents.
 
Testosterone-Replacement Therapy [Free Access]

Testosterone-Replacement Therapy. New England Journal of Medicine 2014;371(21):2032-4. http://www.nejm.org/doi/full/10.1056/NEJMclde1406595

Martin is a generally healthy 61-year-old married man who has come to you for his annual physical examination. His medical history is notable only for gastroesophageal reflux disease and mild hyperlipidemia. His current medications include a proton-pump inhibitor and a statin. He stopped smoking years ago and gets most of his exercise from recreational tennis. He reports consuming a glass or two of wine several nights a week.

As you discuss Martin's health concerns, he mentions an interest in receiving a prescription for testosterone. He says he's heard a lot recently about low testosterone and even took a quiz on a commercial website.

On the basis of his answers to the questions on the quiz — he answered “yes” to questions about decreased energy, decreased ability to play sports, and decreased sexual pleasure and erectile function — the site suggested that he talk to his doctor.

Martin adds that he hasn't heard about any downsides to taking testosterone, and he wonders whether it might improve his concentration at work and his noticeably diminishing stamina while playing tennis.

You complete your physical examination and find no abnormalities of the prostate or testes. Martin's blood pressure is 140/75 mm Hg, and his body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) is 31.5. Martin has no symptoms that suggest sleep apnea.

In addition to ordering standard laboratory tests, you order a test of the total testosterone level, to be determined from a blood sample obtained early in the morning (before 10 a.m.).

Martin's laboratory results are largely unremarkable, including normal values for fasting serum glucose, hematocrit, and thyroid function. The lipid profile shows a high-density lipoprotein (HDL) cholesterol level of 45 mg per deciliter (1.2 mmol per liter), a low-density lipoprotein (LDL) cholesterol level of 85 mg per deciliter (2.2 mmol per liter), and a triglyceride level of 120 mg per deciliter (1.35 mmol per liter). Martin's prostate-specific antigen (PSA) level is 3.5, a level that is stable as compared with the level 1 year earlier.

Of note, his total serum testosterone level is 275 ng per deciliter (9.53 nmol per liter) (normal range, 300 to 950 ng per deciliter [10.4 to 32.9 nmol per liter]). You ask Martin to repeat the early-morning blood test for testosterone, in accordance with current guidelines; the repeat test shows a total testosterone level of 285 ng per deciliter (9.88 nmol per liter).

TREATMENT OPTIONS

Which of the following approaches do you think is appropriate for this patient? Base your choice on the published literature, your own experience, recent guidelines, and other sources of information.

1. Recommend testosterone-replacement therapy

2. Recommend against testosterone-replacement therapy

To aid in your decision making, each of these approaches is defended in a short essay by an expert in the field. Given your knowledge of the patient and the points made by the experts, which option would you choose? Make your choice and make recommendations for the patient at NEJM.org.
 
^^^^^ What would you recommend for Martin?

I would recommend TRT.
His profile is so close to mine that it is almost scary. Same test levels, lipid profile, PSA. Same symptoms except that I can add osteoporosis (which was the reason my doctor asked me it I was interested in TRT). Only difference is that I was about 10 years older when I started TRT and I bike instead of playing tennis.
 
Gandaglia G, Salonia A, Montorsi F. Risk of myocardial infarction in patients receiving testosterone therapy: still a matter of debate. Ann Pharmacother 2014;48(12):1665-6. http://aop.sagepub.com/content/48/12/1665.full.pdf+html

We have read with great interest the article recently published by Baillargeon et al aimed at evaluating the risk of myocardial infarction in men older than 65 years treated with intramuscular testosterone replacement therapy (TRT) for “a potential” late onset hypogonadism, whose characteristics are never precisely defined, except through the procedures codes of Medicare.

As a whole, the authors showed that men receiving TRT were not at increased risk of cardiovascular morbidity compared with a matched cohort of testosterone nonusers. Conversely, testosterone administration was protective against myocardial infarction in a subcohort of patients with increased risk of cardiovascular events at baseline.

Previous investigations reported not univocal results in terms of TRT-related cardiovascular sequelae. Therefore, the study by Baillargeon et al might actually help in clarifying the role of exogenous testosterone in the risk of myocardial infarction in elderly patients.

However, although current observations were obtained in one of the largest available cohorts addressing this issue and the authors of this letter are strongly in favor of a TRT wherever that may be useful, the findings by Baillargeon et al warrant further discussion.

First, it should be noted that the mean number of injections in the entire study period was approximately 8. Nevertheless, more than one-third of the evaluated patients received only 1 testosterone injection over the study period.

In light of this, it is worth mentioning that the only prospective randomized trial showing a detrimental effect of TRT on cardiovascular outcomes included patients using higher and prolonged dosing regimens.

In this context, it is certainly true that the authors also performed subanalyses, including exclusively patients receiving a higher number of injections, but they did not show if such a protective effect of TRT in men with high risk of myocardial infarction persisted.

Second, the nature of this large study performed in Medicare beneficiaries precluded the assessment of the eventual impact of the dose of TRT on the risk of cardiovascular events. Indeed, testosterone dosing identified using Health Care Procedure Coding System drug administration codes ranged between 50 and 200 mg. This might have introduced a significant element of heterogeneity among patients in the treatment arm of the study.

Finally, because the current investigation is based on diagnosis and procedure codes included in charges for outpatient and hospitalization services, the lack of clinically relevant details, which are compulsory to define a condition deserving TRT in the real life scenario, precluded the authors from adjusting their analyses for important cardiovascular risk factors, such as body mass index, blood pressure, familiarity, dietary factors, and recreational habits, including smoking.

In conclusion, we believe that to support the clinical significance of TRT, thus emphasizing safety in the appropriate contexts, further well-designed and well-performed prospective randomized trials are needed to comprehensively assess outcomes of this treatment on the risk of mortality in elderly men.
 
Borst SE, Shuster JJ, Zou B, et al. Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. BMC Med 2014;12(1):211. http://www.biomedcentral.com/1741-7015/12/211

BACKGROUND: Potential cardiovascular (CV) risks of testosterone replacement therapy (TRT) are currently a topic of intense interest. However, no studies have addressed CV risk as a function of the route of administration of TRT.

METHODS: Two meta-analyses were conducted, one of CV adverse events (AEs) in 35 randomized controlled trials (RCTs) of TRT lasting 12 weeks or more, and one of 32 studies reporting the effect of TRT on serum testosterone and dihydrotestosterone (DHT).

RESULTS: CV risks of TRT: Of 2,313 studies identified, 35 were eligible and included 3,703 mostly older men who experienced 218 CV-related AEs. No significant risk for CV AEs was present when all TRT administration routes were grouped (relative risk (RR) = 1.28, 95% confidence interval (CI): 0.76 to 2.13, P = 0.34). When analyzed separately, oral TRT produced significant CV risk (RR = 2.20, 95% CI: 1.45 to 3.55, P = 0.015), while neither intramuscular (RR = 0.66, 95% CI: 0.28 to 1.56, P = 0.32) nor transdermal (gel or patch) TRT (RR = 1.27, 95% CI: 0.62 to 2.62, P = 0.48) significantly altered CV risk. Serum testosterone/DHT following TRT: Of 419 studies identified, 32 were eligible which included 1,152 men receiving TRT. No significant difference in the elevation of serum testosterone was present between intramuscular or transdermal TRT. However, transdermal TRT elevated serum DHT (5.46-fold, 95% CI: 4.51 to 6.60) to a greater magnitude than intramuscular TRT (2.20-fold, 95% CI: 1.74 to 2.77).

CONCLUSIONS: Oral TRT produces significant CV risk. While no significant effects on CV risk were observed with either injected or transdermal TRT, the point estimates suggest that further research is needed to establish whether administration by these routes is protective or detrimental, respectively. Differences in the degree to which serum DHT is elevated may underlie the varying CV risk by TRT administration route, as elevated serum dihydrotestosterone has been shown to be associated with CV risk in observational studies.
 
Morgentaler A. Testosterone deficiency and cardiovascular mortality. Asian J Androl [Epub ahead of print] [cited 2014 Nov 30]. Available from: http://www.ajandrology.com/preprintarticle.asp?id=143248

New concerns have been raised regarding cardiovascular (CV) risks with testosterone (T) therapy (TTh). These concerns are based primarily on two widely reported retrospective studies. However, methodological flaws and data errors invalidate both studies as credible evidence of risk.

One showed reduced adverse events by half in T-treated men but reversed this result using an unproven statistical approach. The authors subsequently acknowledged serious data errors including nearly 10% contamination of the dataset by women.

The second study mistakenly used the rate of T prescriptions written by healthcare providers to men with recent myocardial infarction (MI) as a proxy for the naturally occurring rate of MI.

Numerous studies suggest T is beneficial, including decreased mortality in association with TTh, reduced MI rate with TTh in men with the greatest MI risk prognosis, and reduced CV and overall mortality with higher serum levels of endogenous T. Randomized controlled trials have demonstrated benefits of TTh in men with coronary artery disease and congestive heart failure. Improvement in CV risk factors such as fat mass and glycemic control have been repeatedly demonstrated in T-deficient men treated with T.

The current evidence does not support the belief that TTh is associated with increased CV risk or CV mortality. On the contrary, a wealth of evidence accumulated over several decades suggests that low serum T levels are associated with increased risk and that higher endogenous T, as well as TTh itself, appear to be beneficial for CV mortality and risk.
 
Gonzalez-Sanchez V, Moreno-Perez O, Garcia de Guadiana L, et al. Reference ranges for serum and salivary testosterone in young men of Mediterranean region. Endocrinol Nutr. https://www.sciencedirect.com/science/article/pii/S1575092214002289

BACKGROUND AND AIMS: The interassay variability found in the measurement of testosterone (T) levels warrants the need for laboratories to validate their methods to establish trustworthy cut-off points for diagnosis of male hypogonadism. The aims of this study were to validate measurement of total T (TT) at our laboratory in order to obtain reference ranges for TT, calculated free T (CFT), calculated bioavailable T (CBT), and salivary T (ST) in healthy young men from the Mediterranean region, and to evaluate the potential clinical value of ST by establishing its correlation with serum T.

METHODS: An observational, cross-sectional study with sequential sampling. Inclusion criteria: men aged 18-30 years with body mass index (BMI)<30. Exclusion criteria: chronic diseases, hepatic insufficiency or use of drugs altering circulating T levels. Main outcome measures TT (chemiluminescent immunoassay UniCell DXI 800 [Access T Beckman Coulter]), CFT and CBT (Vermeulen's formula), and ST (radioimmunoassay for serum TT modified for saliva [Coat-A-Count, Siemens]). Descriptive statistical analyses and correlation by Spearman's rho (SPSS 19.0 Inc., Chicago) were used.

RESULTS: One hundred and twenty-one subjects aged 24+/-3.6 years with BMI 24+/-2.5kg/m2 were enrolled. Hormone study: TT, 19+/-5.5nmol/L (reference range [rr.] 9.7-33.3); CFT, 0.38nmol/L (rr. 0.22-0.79); CBT, 9.7nmol/L (rr. 4.9-19.2); and ST, 0.35nmol/L (rr. 0.19-0.68). Correlation between ST and CFT was 0.46.

CONCLUSIONS: In men from the Mediterranean region, values of TT>9.7nmol/L, CFT>0.22nmol/L, and/or CBT>4.9nmol/L make the presence of biochemical hypogonadism unlikely. According to the correlation between serum and ST, the clinical value of ST remains to be established.
 
Back
Top